COMPANY’S THIRD HUMAN FACTORS FORMATIVE STUDY SHOWS THAT 95% OF PARTICIPANTS PREFER THE VAXESS MICROARRAY PATCH TO TRADITIONAL INJECTIONS DEVICES.

WOBURN, Mass, December 4, 2025 — Vaxess Technologies, Inc., a biotech company developing a novel microarray patch (MAP) platform for therapeutics, today announced initial results from the “Vaxess MAP Human Factors Formative Study.” 

“As Vaxess prepares to move forward with its GLP-1 candidate, we wanted to ensure that patients will have a positive experience with the microarray patch, and be able to apply it safely and effectively, ” said Rachel Sha, CEO at Vaxess. “After reviewing the data from our 2025 human factors study, it’s clear that our MAP platform offers a much more patient-friendly GLP-1 delivery mechanism that people can use from the comfort of their homes or easily take with them when they’re traveling.”

This is Vaxess’s third human factors formative study conducted to date, and took place at the Eurofins Human Factors MD research lab in Charlotte, NC. Participants included more than 57 adults with a Body Mass Index (BMI) of 27 to 29.9 and currently taking or previously taken GLP-1 medication, or individuals with a BMI of 30 or higher. Participants were instructed on how to use the MAP applicator and were then asked to apply the adhesive backing of a patch that does not contain GLP-1 medication. Following use, the moderator asked a series of questions to gather ratings and feedback from participants on various topics such as ease of use, acceptability of application at five different levels of force, and perceived pain.

Key Findings

• High Ease of Use Ratings: Each week, following use of the MAP applicator, participants were asked to rate how easy or difficult it was to use the applicator to apply a patch on a scale of 1-5, with 1 being “Extremely Difficult” and 5 being “Extremely Easy.” During each of the study’s three weeks, participants’ average rating for the MAP applicator was consistently higher than 4.4. Nearly all the participants found the MAP applicator easy to use, with some mentioning that the device felt intuitive to use without needing instructions or guidance.

• Favorable Experience Compared to Injections: Each week, following use of the MAP applicator, participants that had recent or current experience giving themselves injections were asked to rate (see figure below) the MAP applicator compared to their injections. Nearly half of the participants that evaluated each concept level had current or recent experience giving themselves injections. In general, most participants reported the MAP applicator was better than giving themselves injections. Each week, participants were asked to indicate which device they would prefer to use: the patch applicator (MAP) or an injection device (e.g., the Ozempic prefilled multi-dose pen). Nearly all participants (95%) preferred the patch applicator. 

In 2026, Vaxess will release the complete findings of its third Human Factors Study, which detail each participants’ initial impressions, experience after first use, and longer-term impressions for the MAP applicator across five levels of application of force.

About Vaxess

Vaxess Technologies is transforming home delivery of next generation therapies. Vaxess's platform combines a proprietary microarray patch and applicator, capable of delivering a wide range of therapies. Advanced biomaterials used for the dissolvable microarray tips enable the greatest levels of dose delivery control, and can be modified to deliver different payloads. Additionally, the patch does not require refrigeration, enabling more cost effective access to therapies.

Vaxess has raised more than $100 million in grant and venture capital funding from groups such as RA Capital Management, Engine Ventures, GHIC, Mission BioCapital. The company has also generated strong clinical and in-vivo proof of concept in the platform with a wide range of molecules. For more information, please visit the company website at www.vaxess.com or send additional inquiries to contact@vaxess.com.